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Severe AS 4.197 [1.6, 11.1] 1.4344 0.4944 8.4165 0.0037
Age (years)* 1.49 [1.1, 2] 0.0399 0.0154 6.7363 0.0094
LVEF (%)** 1.37 [1.0, 1.8] -0.0314 0.0137 5.2349 0.0221
*continuous variable followed in 10 year intervals
**continuous variable followed in -10% intervals
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Numbers Needed to Treat Patients and Numbers Needed to Save Money. The
Clinical and Economic Impact of TAVI and ICD face to face
Flavio L. Ribichini1, Gabriele Pesarini2, Corrado Vassanelli2
1Università di Verona, Verona, Italy, 2University of Verona, Verona, Italy
Background: Ageing, and the ever-increasing complexity of medical care requires an
accurate assessment of the clinical advantages of treatments in relation to economic
burden. A highly rated and conceptually simple indicator of this "weighed" inter-
vention is the number needed to treat (NNT). Treating inoperable aortic stenosis
patients with transcatheter aortic valve implantation (TAVI), as deﬁned in the
PARTNER trial, yields an NNT to save 1 life at 1 year of 5 (and 3.7 at 3 years). Such
a formidable indicator of a "therapeutic-effort-to-clinical-yield" has never been so
categorically proven in the most pivotal endpoint for interventional cardiology, and
has led to a Class-I recommendation for TAVI in the recent European guidelines.
Methods: All European clinical and economic data used to calculate cost-beneﬁt
ratios was derived from publicly available data including peer-reviewed literature and
national payment schedules (GHM for France, G-DRG for Germany, weighted
National/Regional DRG tariffs and TAVI reimbursement.
Results: For the example of ICDs used in secondary prevention, it was estimated that
the mean cost to the payer per death avoided at 1 year was V232,550, V197,098 and
V244,335 for France, Germany and Italy respectively. For TAVI the corresponding
cost per death avoided was V160,090, V150,872 and V122.007. In Italy this is also
compounded by the recent introduction of medical device budget procurement caps.
Conclusions: The clinical data in support of TAVI is now strong and it is calculated
that these impressive results are matched by the economic performance when
comparing against other technologies which are often considered routine in their use.
This argument extends beyond the single comparison of TAVI and ICDs, and we
present here further analysis and examination of NNT as an appropriate measure of
value driven beneﬁts with medical devices.
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Background: TAVI is an emerging therapeutic option in pts with severe AS at high
risk for open heart surgery.Whether pts with AS have increased sympathetic activity
remains to be established and effects of TAVI on sympathetic nervous system is also
unknown. We directly measured Muscle Sympathetic Nerve Activity (MSNA) in
patients with aortic stenosis (AS) before and after transcatheter aortic valve implan-
tation (TAVI) and compared MSNA with control patients.
Methods: we prospectively enrolled 14 patients with severe symptomatic AS treated
by TAVI. Fourteen control patients matched for age, body mass index and unscathed
of AS were also included. All patients underwent MSNA and arterial baroreﬂex gain
(ABG) assessment at baseline and one week.
Results: Pts with AS had lower BP levels, signiﬁcant increase in MSNA
(61.01.7vs55.41.4 burst/min; p<0.05) and a decrease in ABG(2.130.14 vs
3.320.19 %burst/mmHg; p<0.01) compared to controls. TAVI induced an increase
of BP associated with a signiﬁcant decrease of MSNA (from 61.01.7 to 54.11.0
burst/min; p<0.01) and was associated with a signiﬁcant increase of ABG (from
2.130.14 to 3.490.33 %burst/mmHg; p<0.0). One patient without sympathetic
baroreﬂex improvement was the only one with moderate paravalvular aortic regur-
gitation (PAR).This could be interpreted as a result of pressure-induced change in
afferent baroreceptor nerve activity thus leading to an increase of MSNA through
a baroreﬂex-mediated mechanism.
Conclusions: We report for the ﬁrst time, that pt with AS have elevated sympathetic
nervous system (SNS) activity associated to a decrease in sympathetic baroreﬂex gain
and that TAVI normalizes these parameters. This study provide evidences for a new
beneﬁcial effect of TAVI namely normalization of SNS hyperactivity. Additionally,
knowing the deleterious effect of SNA in other cardiovascular diseases such as
hypertension or CHF, the lack of normalization of SNS in the pt with moderate PAR
could help to understand the relationship noticed between these signiﬁcant regurgi-
tations following TAVI and the worse survival associated, without any evidence of
causality to date. However,this pathophysiological concept would need to be further
evaluated.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-732
Predictors of Aortic Arch Type: Implications in Patients with Severe Aortic
Stenosis Being Evaluated for Transcatheter Aortic Valve Replacement
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Background: Type II and III aortic arches (T2-3AAs) are associated with lower
procedural success and higher embolic complications in catheter based interventions.
No deﬁnitive studies identify the cause of these challenging anatomical variations. We
hypothesize the development of T2-3AAs is related to gravitational pull on the AA
and brachiocephalic vessels by the heart over time therefore patients of advanced age
and with increased left ventricular (LV) mass, such as those with severe aortic stenosis
(AS) should have a higher incidence of T2-3AAs.
Methods: We reviewed 216 CT scans of the chest with contrast on patients that had
a 2D echocardiogram done within 1 year. Of these patients 107 were found to have
severe AS and evaluated for transcatheter aortic valve replacement (TAVR). AA type
was determined by CT, then patient's baseline characteristics and echocardiographic
parameters including, but not limited to LV ejection fraction (LVEF), LV mass, LV
mass index, and relative wall thickness were analyzed. Complete data was available in
163 patients. The relationship between these variables and AA type was then tested in
univariate and multivariate models.
Results: Univariate analysis revealed severe AS, increased age, weight, coronary
artery disease, LV mass, and LV mass index and reduced LVEF were signiﬁcantly
correlated with type II and III AAs, however after multivariate analysis, only severe
AS, increased age, and LVEF remained as independent predictors of AA type.Conclusions: Severe AS is the most powerful predictor of T2-3AAs. Advanced age
and reduced LVEF also have a statistically signiﬁcant independent correlation with
T2-3AAs. This observation may explain the previously demonstrated beneﬁt of the
left subclavian approach in these patients and accordingly may merit further investi-
gation into the adequacy and beneﬁt of axillary access as smaller caliber TAVR
delivery systems become available
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Background: Transcatheter aortic valve implantation (TAVI) is an evolving
management strategy for patients with aortic valve disease as an alternative to open
aortic valve replacement. Patients with aortic stenosis (AS) have impaired coronary
ﬂow hemodynamics and this may partially explain the mechanism that causes angina
in this condition. We sought to assess the effect of TAVI on coronary ﬂow reserve
(CFR), an established marker of coronary artery hemodynamic function.
Methods: We enrolled patients undergoing TAVI to have CFR invasively assessed
immediately pre- and post-TAVI (at the time of their TAVI procedure) and again at 6
to 12 months. CFR was recorded as a ratio of average peak velocity, pre- and post-
induction of maximal coronary microvascular hyperemia with administration of
intracoronary adenosine. An intracoronary Doppler probe-tipped coronary ﬂow wire
was utilized for the CFR assessment.
Results: 10 patients were enrolled in the study with 8 having the follow-up evaluation
performed. All patients had impaired CFR prior to TAVI (mean CFR 1.53, 95% CI
1.27 - 1.80). At follow-up invasive assessment there was a signiﬁcant increase in CFR
among the patients (mean % increase in CFR pre-TAVI to follow-up of 46.2%, 95%
CI 16.1 – 76.3%, p<0.01) with a mean CFR of 2.18 (95% CI 1.88 – 2.47) at the
follow up assessment. While there was a signiﬁcant change from baseline pre-TAVIacts/POSTER/Aortic Valve Disease and Treatment B223
